Last reviewed · How we verify
NCT06086379: CCT-COVID
Cognitive Rehabilitation Therapy for COVID-19
NA trial testing Compensatory Cognitive Training for COVID-19 in Post-Acute COVID-19 Syndrome in 70 participants. Enrolling by invitation.
30 June 2026
Quick facts
| Lead sponsor | VA Office of Research and Development |
|---|---|
| Phase | NA |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 70 |
| Start date | 1 July 2024 |
| Primary completion | 30 June 2026 |
| Estimated completion | 31 March 2029 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Compensatory Cognitive Training for COVID-19
- Holistic Cognitive Education
Conditions studied
- Post-Acute COVID-19 Syndrome — all drugs for Post-Acute COVID-19 Syndrome →
Sponsor
VA Office of Research and Development — full company profile →
Who can join
18 and older, any sex, with Post-Acute COVID-19 Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cognitive dysfunction, psychiatric symptoms, functional impairment, and disability following COVID-19 negatively impact Veterans' community functioning and quality of life, contribute to significant human suffering, and are costly to VHA. Rehabilitation is a critical priority for Veterans with long COVID. One promising treatment to improve functioning in Veterans with post-COVID-19 cognitive symptoms is Compensatory Cognitive Training (CCT). Previous studies have found that CCT is feasible, acceptable, and efficacious in Veteran populations with multiple sources of cognitive dysfunction. This randomized controlled trial aims to address important RR\&D priorities by examining feasibility, acceptability, and preliminary efficacy of a COVID-19-specific rehabilitation intervention, CCT for long COVID (CCT-C) compared to a robust control condition. The proposed study has the potential to improve cognitive function, functional independence, and quality of life for Veterans with late or delayed effects of secondary conditions related to COVID-19 infections.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06086379
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Post-Acute COVID-19 Syndrome
Currently open trials in the same condition.
- NCT07189936 — Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS · Phase 2 · recruiting
- NCT05977179 — Dietary Intervention to Mitigate Post-Acute COVID-19 Syndrome · NA · recruiting
- NCT06590324 — A Study of Apabetalone in Subjects With Long -COVID · Phase 2, PHASE3 · recruiting
- NCT06776263 — Dysfunctional Breathing in Post COVID-19 Condition. · recruiting
- NCT05787379 — Care for Veterans Post-COVID-19 · NA · recruiting
Other VA Office of Research and Development trials
Trials by the same sponsor.
- NCT07456150 — Personalizing Veteran Pain Care: Adapting Coaching Interventions to Support Maintenance of Self-Care · Phase 1 · not yet recruiting
- NCT06746727 — The Development of a Transdiagnostic Intervention to Improve Social Functioning and Intimate Relationships Among Veteran · NA · not yet recruiting
- NCT07362576 — Perinatal Peer Support for Veterans With Serious Mental Illness · NA · not yet recruiting
- NCT06766331 — Integrated Care Versus Usual Care for Opioid Use Disorder and Infectious Diseases in Veterans · NA · not yet recruiting
- NCT07397195 — ACT for Veterans With IBD and Mental Health Challenges · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06086379 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by VA Office of Research and Development
- Last refreshed: 30 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06086379.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing